



(51) International Patent Classification:

A61K 9/48 (2006.01) *A61K 47/00* (2006.01)
A61K 31/66 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/US2012/053533

(22) International Filing Date:

31 August 2012 (31.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/529,989 1 September 2011 (01.09.2011) US

(71) Applicant (for all designated States except US): **VASCULAR BIOGENICS LTD.** [IL/IL]; 6 Jonathan Netanyahu Street, 60376 Or Yehuda (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHER, Naamit** [US/IL]; 3 Paldi Street, 76248 Rohovot (IL). **YOUNG, Victor, M.** [GB/US]; 45 Echline Grove, South Queensferry, Edinburgh, Midlothian EH30 9RU (GB). **MCNAUGHTON, Alyn** [GB/GB]; 40 Fiddich Drive, Murieston, Livingston, West Lothian EH54 9HG (GB). **BAKSHAE, Massoud** [GB/GB]; Flat 2/2, 149 Onslow Drive, Glasgow G41 3XA (GB). **WILDING, Ian, Robert** [GB/GB]; 10 Glebe Street, Beeston, Nottingham NG9 IBZ (GB).

(74) Agents: **LONGSWORTH, Gaby, L.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 New York Avenue, N.w., Washington, DC 20005-3934 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FORMULATIONS AND DOSAGE FORMS OF OXIDIZED PHOSPHOLIPIDS




FIG. 9

(57) Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4'-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.